These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34367736)

  • 1. Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma.
    Sosnowska A; Chlebowska-Tuz J; Matryba P; Pilch Z; Greig A; Wolny A; Grzywa TM; Rydzynska Z; Sokolowska O; Rygiel TP; Grzybowski M; Stanczak P; Blaszczyk R; Nowis D; Golab J
    Oncoimmunology; 2021; 10(1):1956143. PubMed ID: 34367736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
    Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
    J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment.
    Pilanc P; Wojnicki K; Roura AJ; Cyranowski S; Ellert-Miklaszewska A; Ochocka N; Gielniewski B; Grzybowski MM; Błaszczyk R; Stańczak PS; Dobrzański P; Kaminska B
    Front Oncol; 2021; 11():703465. PubMed ID: 34504786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
    Rodriguez PC; Quiceno DG; Zabaleta J; Ortiz B; Zea AH; Piazuelo MB; Delgado A; Correa P; Brayer J; Sotomayor EM; Antonia S; Ochoa JB; Ochoa AC
    Cancer Res; 2004 Aug; 64(16):5839-49. PubMed ID: 15313928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.
    Miret JJ; Kirschmeier P; Koyama S; Zhu M; Li YY; Naito Y; Wu M; Malladi VS; Huang W; Walker W; Palakurthi S; Dranoff G; Hammerman PS; Pecot CV; Wong KK; Akbay EA
    J Immunother Cancer; 2019 Feb; 7(1):32. PubMed ID: 30728077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade.
    Aaboe Jørgensen M; Ugel S; Linder Hübbe M; Carretta M; Perez-Penco M; Weis-Banke SE; Martinenaite E; Kopp K; Chapellier M; Adamo A; De Sanctis F; Frusteri C; Iezzi M; Zocca MB; Hargbøll Madsen D; Wakatsuki Pedersen A; Bronte V; Andersen MH
    Cancer Immunol Res; 2021 Nov; 9(11):1316-1326. PubMed ID: 34518197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8
    Zhang Md J; Zhang Md L; Yang Md Y; Liu Md Q; Ma Md H; Huang Md A; Zhao Md Y; Xia Md Z; Liu Md T; Wu Md G
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1533-1546. PubMed ID: 33238192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 9. Neutralization of NET-associated human ARG1 enhances cancer immunotherapy.
    Canè S; Barouni RM; Fabbi M; Cuozzo J; Fracasso G; Adamo A; Ugel S; Trovato R; De Sanctis F; Giacca M; Lawlor R; Scarpa A; Rusev B; Lionetto G; Paiella S; Salvia R; Bassi C; Mandruzzato S; Ferrini S; Bronte V
    Sci Transl Med; 2023 Mar; 15(687):eabq6221. PubMed ID: 36921034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity.
    Ramji K; Grzywa TM; Sosnowska A; Paterek A; Okninska M; Pilch Z; Barankiewicz J; Garbicz F; Borg K; Bany-Laszewicz U; Zerrouqi A; Pyrzynska B; Rodziewicz-Lurzynska A; Papiernik D; Sklepkiewicz P; Kedzierska H; Staruch A; Sadowski R; Ciepiela O; Lech-Maranda E; Juszczynski P; Mackiewicz U; Maczewski M; Nowis D; Golab J
    Sci Rep; 2022 Nov; 12(1):19660. PubMed ID: 36385153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid Cell-Derived Arginase in Cancer Immune Response.
    Grzywa TM; Sosnowska A; Matryba P; Rydzynska Z; Jasinski M; Nowis D; Golab J
    Front Immunol; 2020; 11():938. PubMed ID: 32499785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginase 1 is a key driver of immune suppression in pancreatic cancer.
    Menjivar RE; Nwosu ZC; Du W; Donahue KL; Hong HS; Espinoza C; Brown K; Velez-Delgado A; Yan W; Lima F; Bischoff A; Kadiyala P; Salas-Escabillas D; Crawford HC; Bednar F; Carpenter E; Zhang Y; Halbrook CJ; Lyssiotis CA; Pasca di Magliano M
    Elife; 2023 Feb; 12():. PubMed ID: 36727849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
    Doshi AS; Cantin S; Hernandez M; Srinivasan S; Tentarelli S; Griffin M; Wang Y; Pop-Damkov P; Prickett LB; Kankkonen C; Shen M; Martin MS; Wu S; Castaldi MP; Ghadially H; Varnes J; Gales S; Henry D; Hoover C; Mele DA; Simpson I; Gangl ET; Mlynarski SN; Finlay MRV; Drew L; Fawell SE; Shao W; Schuller AG
    Mol Cancer Ther; 2023 May; 22(5):630-645. PubMed ID: 36912782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased number of arginase 1-positive cells in the stroma of carcinomas compared to precursor lesions and nonneoplastic tissues.
    Jang TJ; Kim SA; Kim MK
    Pathol Res Pract; 2018 Aug; 214(8):1179-1184. PubMed ID: 29970307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
    Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.
    Glöckner HJ; Martinenaite E; Landkildehus Lisle T; Grauslund J; Ahmad S; Met Ö; Thor Straten P; Hald Andersen M
    Oncoimmunology; 2024; 13(1):2318053. PubMed ID: 38404966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway.
    Ren X; Wang N; Zhou Y; Song A; Jin G; Li Z; Luan Y
    Acta Biomater; 2021 Apr; 124():179-190. PubMed ID: 33524560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
    Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
    J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
    Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
    J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.